Operationalize Cell & Gene Therapies

Making Commercialization Predictable

As the industry focuses more on specialty therapies, it is imperative that manufacturers move to a patient-centered care model that delivers value enabled by innovative technologies and measured by actionable data.

As the only go-to complete commercialization expert in the industry, we bring together strategy, patient recruitment for clinical trials, HCPs and patient engagement across the patient journey, and warehousing and logistics to support complex transportation needs.

The inherent complexity of regenerative therapies impacts distribution, access, affordability and patient support.

Supply chain and technology are two primary areas of focus that cell therapy manufacturers need to bring a very different lens and set of capabilities to successfully commercialize their products.

Schedule a meeting with an EVERSANA cell and gene therapy expert to learn more.

  • Three Keys To Value For Unlocking the Promise of Cell Therapies

    Understand the requirements for realizing the true potential of cell and gene therapies.

    Learn More
  • The Power Of Working Together with the Rare Disease Community

    Learn how to drive success with a gene therapy launch by understanding the journey of the rare disease patient.

    Learn More
  • How do we pay for a cure?

    Setting drug prices is a high-stakes endeavor, and that is especially true for the latest round of gene and curative products.

    Learn More

Make the Commercialization of Cell & Gene Therapies Predictable with these Solutions



    Built for the pharmaceutical and biotechnology industries, our global experts help industry executives address their most pressing business challenges.

    Learn More


    This new multi stakeholder era of healthcare demands a strategic and creative partner who’s adept at making connections among patients, providers, and payers.

    Learn More
  • Global Channel & 3PL

    Global Channel & 3PL

    Rely on us to manage all unique handling and individualized transportation needs, including urgent access programs for critical patient needs.

    Learn More

Recent Partnerships to Advance Cell & Gene Therapies

Vineti and EVERSANA™ form strategic alliance to advance patient-centered services and supply chain automation for regenerative medicine

This alliance between two industry leaders integrates Vineti’s Personalized Therapy Management (PTM) platform with EVERSANA’s comprehensive, integrated commercial services to support cell and gene therapy innovators bring their products to patients in a faster, more effective, and data-driven supply chain. Read the full story.

“We are partnering with best-in-class technology providers like Vineti who share our vision for an accelerated regenerative medicine pipeline that gets products to patients safely, effectively and in a value- and data-driven model. Innovators carry less risk and more financial predictability, while their patients have the promise of healthier lives.”


Cryoport and EVERSANA Form Strategic Alliance to Accelerate Regenerative Medicine Supply Chain

The alliance will be designed to leverage EVERSANA’s position as the leading provider of commercial services addressing access, affordability and adherence challenges for cell and gene therapies and Cryoport’s complete suite of temperature-controlled logistics solutions to ensure a safe and effective supply chain solution for innovative therapeutic advancements. Read the full story.

“Through our alliance, Cryoport will provide EVERSANA and its clients with our full suite of logistics solutions under our ‘powered by cryoport™’ marketing model. This includes our Cryoport Express® Shippers, Cryoportal® Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and our advanced logistics management.”

Jerrell Shelton, CEO, Cryoport

Contact Us to learn more about our Cell & Gene Therapy Solutions.

Contact Form

  • This field is for validation purposes and should be left unchanged.